SCHEDULE 13G/A: RA Capital Management Group Discloses 8.9% Stake in Verona Pharma plc
Amendment to Beneficial Ownership Statement
RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.9% in Verona Pharma plc as of December 31, 2024.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") filed an Amendment No. 5 to Schedule 13G.
- The filing reports their beneficial ownership in Verona Pharma plc's Ordinary Shares as of December 31, 2024.
- The aggregate amount beneficially owned by the Reporting Persons is 7,777,942 Ordinary Shares.
- This represents 8.9% of the total outstanding Ordinary Shares of Verona Pharma plc.
- The ownership includes 1,766,830 American Depository Shares (ADSs), equivalent to 14,134,640 Ordinary Shares, and 48,088,896 non-voting Ordinary Shares (equivalent to 6,011,112 ADSs) held by RA Capital Healthcare Fund, L.P.
- Each ADS represents 8 Ordinary Shares.
- RA Capital Management, L.P. serves as the investment adviser for RA Capital Healthcare Fund, L.P., holding shared voting and dispositive power over the reported securities.
- A "Beneficial Ownership Blocker" prevents the redesignation of non-voting Ordinary Shares if it would result in the holder (with affiliates/group) owning more than 9.99% of outstanding Ordinary Shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It neither highlights positive nor negative operational or financial performance.
Risks
- The "Beneficial Ownership Blocker" limits the ability of RA Capital Healthcare Fund, L.P. to convert its non-voting shares into voting Ordinary Shares if it would result in ownership exceeding 9.99% of the outstanding shares, potentially limiting their influence.
Industry Context
This filing is a routine disclosure by a significant institutional investor, RA Capital Management, L.P., detailing its beneficial ownership stake in Verona Pharma plc. Such filings provide transparency into major shareholdings, which can be of interest to other investors tracking institutional confidence or potential strategic moves within the biotechnology or pharmaceutical sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Beneficial Ownership Limitation | The agreement governing the terms of the Redesignation Right for Non-Voting Ordinary Shares contains a 'Beneficial Ownership Blocker,' which prevents the redesignation of these shares if it would result in the holder, together with affiliates, beneficially owning more than 9.99% of the Ordinary Shares outstanding. | NA | This provision limits the potential voting power and influence of RA Capital Healthcare Fund, L.P. by capping their ability to convert non-voting shares into voting shares beyond a certain threshold, thereby maintaining a dispersed ownership structure. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially signal confidence or strategic interest in Verona Pharma plc.
Key Dates
| Date | Description |
|---|---|
| 2024-10-28 | Date as of which 654,649,358 outstanding Ordinary Shares were reported in Issuer's Form 10-Q. |
| 2024-11-04 | Date Issuer's Form 10-Q was filed, reporting outstanding Ordinary Shares as of October 28, 2024. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-02-14 | Date of the Joint Filing Agreement and signature date for the Schedule 13G/A. |
Keywords
Verona Pharma plc, RA Capital Management, Schedule 13G/A, Beneficial Ownership, Ordinary Shares, ADSs, Institutional Investor, SEC Filing, Healthcare Fund, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.